Overview
Samuel Kerr is a Hematologist and an Oncologist in Lancaster, Pennsylvania. Dr. Kerr is rated as an Experienced provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Non-Small Cell Lung Cancer (NSCLC). Dr. Kerr is currently accepting new patients.
His clinical research consists of co-authoring 3 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- MEDICARE PDP
- EPO
- HMO
- POS
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER COMMERCIAL
- OTHER MEDICARE PART D
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE SNP
- OTHER MEDICARE PART D
- HMO
- POS
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE SNP
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- PPO
- HMO
- MANAGED MEDICAID PLAN
- EPO
- HMO
- POS
- PPO
- EPO
- PPO
- MEDICARE DISCOUNT CARD
- MEDICARE PDP
- OTHER MEDICARE
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
2102 Harrisburg Pike, Lancaster, PA 17601
Additional Areas of Focus
Dr. Kerr has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
1 Clinical Trials
Skip Viragh Outpatient Cancer Center
Dr. Michael A. Carducci is the AEGON Professor in Prostate Cancer Research at the Johns Hopkins University School of Medicine. He serves as the Vice Chair of Solid Tumor Oncology in the Department of Oncology. Dr. Carducci has an expertise in various types of cancer including prostate, kidney, and testicular. He also has an expertise in clinical trials, pain and palliative care for oncology, urological oncology, urology and medical oncology. A graduate of Georgetown University, Dr. Carducci received his medical degree with high distinction from Wayne State University School of Medicine. He completed an internal medicine internship, residency and chief residency at the University of Colorado Health Sciences Center. He went on to complete medical oncology and research fellowships at the Johns Hopkins Oncology Center at Johns Hopkins Hospital. He was promoted to Professor of Oncology and Urology in 2008 and installed into the inaugural AEGON Professorship in Prostate Cancer Research in 2009. He served as Co-Director of the GU Oncology program until 2013. In 2013, he assumed the leadership role of Associate Director for Clinical Research until being named Vice-Chair of Solid Tumor Oncology in 2024. A fellow of the American College of Physicians and a fellow of the American Society of Clinical Oncology, Dr. Carducci has received peer-reviewed funding for his clinical research from the National Cancer Institute, Department of Defense, and the Prostate Cancer Foundation. Mentorship of students, fellows, and junior faculty has been another focus of Dr. Carducci’s career in medicine, receiving numerous teaching awards. Dr. Carducci received the Michaele Christian Award and Lectureship for Oncology Drug Development at the National Cancer Institute in 2011. He chaired the Genitourinary Oncology Committee of ECOG-ACRIN from 2011-2024. In this role, he served on the GU Steering Committee for the NCI. Dr. Carducci is a member of the Investigational Drug Steering Committee for the NCI, and chaired that Committee for four years. He served as Associate Editor for GU Cancers for the Journal of Clinical Oncology from 2013-2024. Overall, his clinical research focus is on the development and evaluation of new therapies for urologic cancers. Incorporation of pharmacodynamics, novel biomarkers, and targeted imaging has been key elements of many of the trials led by Dr. Carducci. To complete these studies, Dr. Carducci facilitates and brings together a multidisciplinary team from urologists, radiation oncologists, pathologists, biostatisticians, and medical oncologists. Other areas of interest include palliative and end of life care, survivorship, and use of patient reported outcomes in clinical research and care. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Carducci is rated as an Elite provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Orchiectomy.
Johns Hopkins Outpatient Center
Dr. Christian Pavlovich is Bernard L. Schwartz Distinguished Professor in Urologic Oncology at the Johns Hopkins University School of Medicine and Director of the Prostate Cancer Active Surveillance Program at the Brady Urological Institute. Dr. Pavlovich treats cancer with an emphasis on minimizing morbidity and maximizing quality of life while offering patients the latest treatment options and techniques. His clinical focus is on prostate and kidney cancer, and on clinical trials regarding detection, surveillance, and immunotherapy. With more than 20 years of experience with minimally-invasive surgery for the treatment of urologic cancers, he is expert in robotic surgery and was named one of the top prostate cancer surgeons in the United States by Newsweek in 2024. In addition, he offers patients modern diagnostic biopsy techniques, and for prostate cancer patients active surveillance and ablative options including cryotherapy and TULSA. Dr. Pavlovich grew up in Washington DC, went to Harvard University, and then earned his medical degree at the University of California, San Francisco (UCSF) School of Medicine. He then completed a urology residency at New York Hospital-Cornell Medical Center and a National Cancer Institute SUO fellowship in urologic oncology before joining the Hopkins faculty in 2001. Dr. Pavlovich has published over 150 peer-reviewed articles, is Associate Editor of The Prostate and is on the Editorial Board of the British Journal of Urology International. He was the inaugural Director of the Brady Urological Institute’s SUO Urologic Oncology Fellowship (2014 -2024) and is the recipient of three “best teaching/research mentor” awards from the Urology residents at Johns Hopkins. Dr. Pavlovich speaks English, French, Spanish, German, and Serbo-Croatian. He enjoys spending time with his wife and children, following their pursuits, and skiing, diving, running, wildlife, and the great outdoors. Dr. Pavlovich is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Nephrectomy.
Abramson Cancer Center Perelman 2nd Floor West
Vivek Narayan is an Oncologist in Philadelphia, Pennsylvania. Dr. Narayan is rated as a Distinguished provider by MediFind in the treatment of Familial Prostate Cancer. His top areas of expertise are Prostate Cancer, Hemangioblastoma, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, and Prostatectomy. Dr. Narayan is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- ALK-Positive Non-Small Cell Lung CancerDr. Kerr isDistinguished. Learn about ALK-Positive Non-Small Cell Lung Cancer.
- EGFR Positive Lung CancerDr. Kerr isDistinguished. Learn about EGFR Positive Lung Cancer.
- Essential ThrombocythemiaDr. Kerr isDistinguished. Learn about Essential Thrombocythemia.
- Large-Cell Lung CarcinomaDr. Kerr isDistinguished. Learn about Large-Cell Lung Carcinoma.
- Lung AdenocarcinomaDr. Kerr isDistinguished. Learn about Lung Adenocarcinoma.
- Lung CancerDr. Kerr isDistinguished. Learn about Lung Cancer.
- Advanced
- Adult Immune ThrombocytopeniaDr. Kerr isAdvanced. Learn about Adult Immune Thrombocytopenia.
- AngiosarcomaDr. Kerr isAdvanced. Learn about Angiosarcoma.
- B-Cell LymphomaDr. Kerr isAdvanced. Learn about B-Cell Lymphoma.
- Breast CancerDr. Kerr isAdvanced. Learn about Breast Cancer.
- Chronic B-Cell Leukemia (CBCL)
- Chronic Lymphocytic Leukemia (CLL)
- Experienced
- Acute Eosinophilic PneumoniaDr. Kerr isExperienced. Learn about Acute Eosinophilic Pneumonia.
- Acute Lymphoblastic Leukemia (ALL)Dr. Kerr isExperienced. Learn about Acute Lymphoblastic Leukemia (ALL).
- Acute Myeloblastic Leukemia with Maturation
- Acute Myeloblastic Leukemia without Maturation
- Acute Myeloid Leukemia (AML)Dr. Kerr isExperienced. Learn about Acute Myeloid Leukemia (AML).
- Adult Soft Tissue SarcomaDr. Kerr isExperienced. Learn about Adult Soft Tissue Sarcoma.


